Active	Status	Sponsor type	Region	Phase	Filter
25 Active 6 Inactive 31 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cheung, Angela M
NCT01896011: Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures	Completed	3	34	Canada	Teriparatide 20 mcg, Brand name Forteo, Placebo	University Health Network, Toronto, The Physicians' Services Incorporated Foundation, Eli Lilly and Company	Non Displaced Atypical Femoral Fractures	12/21	12/22
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites	Completed	3	410	Europe, Canada, US, RoW	Albutein 20% Injectable Solution, Standard medical treatment	Grifols Therapeutics LLC, Instituto Grifols, S.A.	Decompensated Cirrhosis and Ascites	05/24	05/24
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)	Active, not recruiting	3	238	Europe, Canada, Japan, US, RoW	Linerixibat, Placebo	GlaxoSmithKline	Pruritus	10/24	01/25
ESSOR, NCT05999435: Study of LAU-7b for the Treatment of Long COVID in Adults	Active, not recruiting	2/3	272	Canada	LAU-7b for 3 cycles, fenretinide, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles, sugar pill	Laurent Pharmaceuticals Inc.	Long COVID	08/24	10/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)	Terminated	1	16	Europe, Canada, US, RoW	SAR439459, Placebo	Sanofi	Osteogenesis Imperfecta	11/24	11/24
NCT01155245: Teriparatide (PTH) and Bone Strength in Postmenopausal Women	Active, not recruiting	N/A	60	Canada	Forteo	University Health Network, Toronto, Eli Lilly and Company	Osteoporosis	01/24	01/25
Saal, Howard
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia	Active, not recruiting	2	84	Europe, Canada, US, RoW	Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg	QED Therapeutics, Inc.	Achondroplasia	10/24	12/24
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)	Terminated	1	16	Europe, Canada, US, RoW	SAR439459, Placebo	Sanofi	Osteogenesis Imperfecta	11/24	11/24
PROPEL, NCT04035811: Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)	Recruiting	N/A	250	Europe, Canada, US, RoW		QED Therapeutics, Inc.	Achondroplasia	06/26	06/26
Jain, Mahim
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)	Terminated	1	16	Europe, Canada, US, RoW	SAR439459, Placebo	Sanofi	Osteogenesis Imperfecta	11/24	11/24
Ho, Irene
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)	Terminated	1	16	Europe, Canada, US, RoW	SAR439459, Placebo	Sanofi	Osteogenesis Imperfecta	11/24	11/24
Nguyen, Dianne
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)	Terminated	1	16	Europe, Canada, US, RoW	SAR439459, Placebo	Sanofi	Osteogenesis Imperfecta	11/24	11/24